IP Library › Granted Patent US 7,951,368
Granted Patent B2
US 7,951,368 · App. 12/146,431 · Granted May 31, 2011

Compositions of specific binding agents to hepatocyte growth factor

Assignee: Amgen Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,951,368
App. No.
12/146,431
Granted
May 31, 2011
Kind
B2
Abstract

Compositions comprising nonpolar amino acids and specific binding agents to hepatocyte growth factor (HGF) are provided. Methods of making and using such compositions are also provided.

Claims (9)

1. A composition comprising a specific binding agent to HGF, at least one stabilizing agent, and a buffering agent, wherein the at least one stabilizing agent comprises alanine and leucine, and wherein the pH of the composition is above 5.4.

2. The composition of claim 1 , wherein the specific binding agent is selected from an antibody, a polyclonal antibody, a monoclonal antibody, an antibody wherein the heavy chain and the light chain are connected by a flexible linker, an Fv molecule, a maxibody, an immunologically functional immunoglobulin fragment, a Fab fragment, a Fab′ fragment, a F(ab′) 2 molecule, a fully human antibody, a humanized antibody, a chimeric antibody, and an antibody that substantially inhibits binding of HGF to a c-Met receptor.

3. The composition of claim 2 , wherein the specific binding agent is a fully human antibody, wherein the fully human antibody is 2.12.1.

4. The composition of claim 1 , further comprising at least one additional pharmaceutical agent.

5. The composition of claim 1 , wherein the at least one stabilizing agent further comprises methionine, and wherein discoloration of the composition is reduced.

6. The composition of claim 1 , wherein the at least one stabilizing agent further comprises at least one cryoprotectant.

7. The composition of claim 6 , wherein the at least one cryoprotectant is selected from polyvinylpyrrolidone K15, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 4000, and polyethylene glycol 30,000.

8. The composition of claim 6 , wherein the at least one stabilizing agent further comprises methionine, and wherein discoloration of the composition is reduced.

9. The composition of claim 8 , wherein the at least one cryoprotectant is selected from polyvinylpyrrolidone K15, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 4000, and polyethylene glycol 30,000.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2010
From: LI, TIANSHENG; RAJAN, RAHUL; HUANG, ZHUOHONG; NAGAPUDI, KARTHIK; LUERAS, ALEXIS; AOKI, MARIKO; CHU, GRACE C.
To: AMGEN INC.
Reel/Frame 024580/0943 →
Continuity (2)
Provisional Application 60937283 · Jun 25, 2007
Related Publication 20090042315A1 · Feb 12, 2009